Skip to main content

Quest Diagnostics Value Stock - Dividend - Research Selection

Quest diagnostics

ISIN: US74834L1008 , WKN: 904533

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company\'s Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. Its Diagnostic Solutions segment offers risk assessment services for the life insurance industry; and health information technology solutions for healthcare organizations and clinicians. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Explore the top gainers and losers within the S&P500 index in today's session.

2026-04-21
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Tuesday.

Quest (DGX) Q1 2026 Earnings Transcript

2026-04-21
During the first quarter, we grew revenues over 9%, almost entirely from organic revenue growth on broad-based demand for our clinical innovations, expansion into new clinical areas and collaborations with elite health care and consumer health organizations. Quest operates at the center of health care, delivering solutions that make testing simpler and smarter for our core clinical customers, physicians and hospitals as well as customers in higher-growth areas of consumer health, life sciences and data analytics. In the physician channel, we delivered high single-digit revenue growth in the first quarter on strong demand for our clinical innovations, geographic expansion from greater health plan access and increased volume from our growing business in enterprise accounts.

Quest Diagnostics Incorporated Q1 2026 Earnings Call Summary

2026-04-21
Moby summary of Quest Diagnostics Incorporated's Q1 2026 earnings call

Top S&P500 movers in Tuesday's session

2026-04-21
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Tuesday as we examine the latest happenings in today's session.

Quest (DGX) Q4 2024 Earnings Transcript

2026-04-21
In the fourth quarter, we delivered impressive revenue growth of nearly 15%, including approximately 5% organic growth, while also improving our profitability. For the full year, we drove revenue growth of close to 7%, including approximately 3% organic growth. In 2024, our team completed eight acquisitions, including LifeLabs in Canada and four hospital outreach lab businesses in the US.

Quest (DGX) Q1 2025 Earnings Transcript

2026-04-21
In the first quarter, we delivered strong revenue growth of approximately 12%, including nearly 2.5% in organic growth as demand rebounded in March following weather impacts early in the quarter. The court's decision will ensure patients and providers can continue to access innovative laboratory testing services regulated under CLIA without additional regulatory costs to comply with the FDA LDT rule.

Quest Diagnostics Q1 Earnings Call Highlights

2026-04-21
Quest Diagnostics (NYSE:DGX) reported first-quarter 2026 results that management said reflected broad-based organic growth, improving productivity from automation and artificial intelligence, and contributions from major collaborations including Fresenius Medical Care and Corewell Health. The compan

Which S&P500 stocks are gapping on Tuesday?

2026-04-21
Wondering what's happening in today's session regarding gap up and gap down stocks? Explore the S&P500 index on Tuesday to uncover the stocks that are gapping in the S&P500 index.

The Most Impressive Part Of Quest Diagnostics Stock-Spiking First-Quarter Report

2026-04-21
Quest Diagnostics bucked concerns Tuesday that storms would wash out its first-quarter report. The stock jumped on a beat and raise.

Quest Diagnostics' Q1 Earnings & Revenues Top Estimates, Stock Up

2026-04-21
DGX posts Q1 2026 earnings and revenue beat, with adjusted EPS up 13% and shares rising in pre-market trading.